Amarin Corp Plc (AMRN)

[funnygi2]

HD - re 164190

I always thought it was this:

Also under the Laxdale agreement, upon receipt of marketing approval in Europe for the first indication for Vascepa (or first indication of any product containing Amarin Neuroscience Limited intellectual property acquired from Laxdale in 2004), we must make an aggregate stock or cash payment to the former shareholders of Laxdale (at the sole option of each of the sellers) of £7.5 million (approximately $9.8 million as of September 30, 2018).

From page 46, 10q 9/30/18